Gnosis has received ANVISA approval to introduce the probiotic yeast *Saccharomyces boulardii* in Brazilian pharmaceutical market.

**DESIO, Italy – April 11th 2011**

Gnosis is pleased to announce that its manufacturing Operations, Gnosis Bioresearch SA, located in Sant’Antonino, Switzerland, has been successfully inspected by ANVISA, the Brazilian National Health Surveillance Agency, and has received approval for the commercialization of the probiotic yeast *Saccharomyces boulardii* in Brazil.

The Sant’Antonino facility has already achieved GMP approval by Swiss Medic in 2005 as well as Kosher certification. Pharmaceutical production of *S. boulardii* began in 2007 and a DMF was submitted in 2008.

Commenting on the successful inspection of Gnosis, Fulvio Carlotti, Corporate QA Director of the company said: “This new recognition by ANVISA strengthens our international position as a global pharmaceutical supplier of *S. boulardii*. It also represents a significant milestone for Gnosis’ representation in the South America market and demonstrates our ability to comply with the strict rules required by ANVISA and the high quality of our product.”

*S. boulardii* is a well-researched probiotic yeast with therapeutic uses in the prophylaxis and treatment of intestinal dismicrobism and disvitaminosis induced by antibiotics and sulphonamides, the therapy of acute diarrhea of various etiology, the prophylaxis and treatment of traveler’s diarrhea, the therapy of irritable bowel syndrome as well as the treatment of candidiasis.